EMEA Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2018

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Glucagon Like Peptide-1 (GLP-1) Agonists for these regions, from 2013 to 2025 (forecast)

•     Europe: Germany, France, UK, Russia, Italy and Benelux;
•     Middle East: Saudi Arabia, Israel, UAE and Iran;
•     Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Glucagon Like Peptide-1 (GLP-1) Agonists market competition by top manufacturers/players, with Glucagon Like Peptide-1 (GLP-1) Agonists sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

•     Novo Nordisk
•     AstraZeneca
•     Eli Lilly
•     GSK
•     Sanofi
•     Bristol-Myers Squibb
•     Amylin

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

•     Exenatied
•     Liraglutide
•     Lixisenatide
•     Albiglutide
•     Dulaglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

•     Hospital
•     Pharmacy
•     Other